Deepak Bhatt, MD, discusses a presentation he gave at ESC Congress 2021 on SGLT2, 1/2 inhibition and reflects on the potential for sotagliflozin to receive approval from the FDA based on data from SOLOIST-WHF and SCORED.
Although SGLT2 inhibitors have put the ‘flozins’ at centerstage at recent cardiology conferences, a unique newcomer to the group has been making waves since a pair of phase 3 trials were presented at the American Heart Association 2020 Annual Meeting.
A dual SGLT1/2 inhibitor, sotagliflozin made a splash in late 2020 with the SOLOIST-WHF and SCORED trials, which demonstrated the agent provided meaningful benefit in patients with diabetes and chronic kidney disease or heart failure. Despite impressive data from its phase 3 program, sotagliflozin has no existing FDA indications, unlike other SGLT2 inhibitors.
The subject of SLGT1/2 inhibition and its effect on cardiovascular and kidney endpoints was the subject of a late-breaking presentation led by principal investigator of the SOLOIST-WHF and SCORED trials Deepak Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, at the European Society of Cardiology (ESC) Congress 2021. With an interest in learning more about sotagliflozin and its potential for receiving an FDA indication in the future, we reached to Bhatt for more perspective and that conversation is the subject of this ESC Congress 2021 House Call.